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CD4+ T cells are crucial for effective repression and elimination of cancer cells. Despite a
paucity of CD4+ T cell receptor (TCR) clinical studies, CD4+ T cells are primed to become
important therapeutics as they help circumvent tumor antigen escape and guide
multifactorial immune responses. However, because CD8+ T cells directly kill tumor
cells, most research has focused on the attributes of CD8+ TCRs. Less is known about
how TCR afﬁnity and CD4 expression affect CD4+ T cell activation in full length TCR (ﬂTCR)
and TCR single chain signaling (TCR-SCS) formats. Here, we generated an afﬁnity panel of
TCRs from CD4+ T cells and expressed them in ﬂTCR and three TCR-SCS formats
modeled after chimeric antigen receptors (CARs) to understand the contributions of TCRpMHCII afﬁnity, TCR format, and coreceptor CD4 interactions on CD4+ T cell activation.
Strikingly, the coreceptor CD4 inhibited intermediate and high afﬁnity TCR-construct
activation by Lck-dependent and -independent mechanisms. These inhibition
mechanisms had unique afﬁnity thresholds dependent on the TCR format. Intracellular
construct formats affected the tetramer staining for each TCR as well as IL-2 production.
IL-2 production was promoted by increased TCR-pMHCII afﬁnity and the ﬂTCR format.
Thus, CD4+ T cell therapy development should consider TCR afﬁnity, CD4 expression,
and construct format.
Keywords: CD4, T cell receptor, afﬁnity, chimeric antigen receptor, Lck, helper T cell

INTRODUCTION
CD4+ T cells are critical for tumor elimination through both indirect and direct mechanisms.
Indirectly, CD4+ T cells target tumor cells by activating tumor-killing cells such as CD8+ T cells,
macrophages, B cells, and natural killer cells (1–4). CD4+ T cells have direct cytotoxic effects against
tumor cells that express major histocompatibility complex II (MHCII) (1–4) and direct CD4+ T cell
responses are less toxic to the patient than a CD8+ T cell response, especially when responding to
overexpressed tumor associated antigens (TAA) (5). The presence of tumor-speciﬁc CD4+ T cells is
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LLO190-205 peptide presented by the MHCII molecule I-Ab with
similar afﬁnity (41, 42). LLO118 has a more robust primary
response and LLO56 has a more robust secondary response,
indicating that TCR afﬁnity is not the only parameter affecting
activation in these cells. To examine the role of afﬁnity in the
activation responses of LLO56 and LLO118, we engineered an
afﬁnity panel of CD4+ TCRs (ranging from 4 µM to 200 nM)
using yeast display (43, 44). After characterizing their afﬁnity and
avidity, the activation characteristics of two low afﬁnity clones,
two intermediate afﬁnity clones, and one high afﬁnity clone were
examined in the full length TCR (ﬂTCR) format or in three TCRSCS CAR formats (CD28- and 4-1BB-based second generation
CARs, and CD28/4-1BB third generation CAR). T cell receptor
single-chain signaling chimeric antigen receptors (TCR-SCS
CARs) are an exciting potential therapeutic option and as
CD4+ T cells are potent responders to cancer, we sought to
understand how CD4+ TCRs respond to a variety of afﬁnities.
TCR-SCSs constructs avoid mispairing with endogenous TCR
chains, which is an inherent risk for engineered ﬂTCRs (45).
CARs also produce more cytokines and are activated by higher
antigen densities than ﬂTCRs and may be more likely to ignore
healthy cells with low amounts of TAAs, which may improve
clinical outcomes (46–48).
We found that increased TCR afﬁnity promotes production of
IL-2 regardless of ﬂTCR or TCR-SCS format. The ﬂTCRs are
more responsive to lower amounts of peptide stimulation, and
contrary to CD8+ TCR ﬁndings (49), produce more cytokine
than TCR-SCSs. While there are some observable trends
dependent on second and third generation TCR-SCS CAR
format, IL-2 production varies depending on whether the
TCRs were engineered from the LLO56 or LLO118 TCRs. CD4
promotes the activation of low afﬁnity ﬂTCRs and TCR-SCSs,
but CD4 is inhibitory in intermediate afﬁnity ﬂTCR and high
afﬁnity TCR-SCS CARs. The ﬂTCR reaches CD4 inhibition at a
lower afﬁnity than TCR-SCSs, suggesting that ﬂTCRs perceive a
stronger initial activation signal. These ﬁndings suggest that
therapeutic CD4 TCR development should consider construct
features, TCR afﬁnity, and coreceptor activation contributions
when choosing or engineering therapeutic TCRs and cell lines.

correlated with improved patient survival following vaccination
with cancer-associated peptides whether or not they are directly
involved in tumor suppression (6–8). Furthermore, CD4+ T cells
can sustain an immune response when CD8+-speciﬁc antigens
are lost which otherwise might result in tumor escape (9).
Despite these clear beneﬁts, only one published clinical study
(10) focuses on the immunotherapeutic beneﬁts of CD4+ T cell
receptors (TCRs) (10, 11).
CD4+ T cells are activated by interactions between the TCR
and its cognate peptide presented on MHCII (pMHCII) (12).
TCRs can detect a single amino acid change and distinguish
between self-proteins and mutated neoantigens (11), uniquely
suiting TCR-based therapies for speciﬁc tumor targeting.
Furthermore, unlike antibody-based chimeric antigen receptors
(CARs), which are limited to extracellular targets, TCRs can
target intracellular antigens presented by MHC molecules (11).
To rationally design optimal targeting strategies, it is essential to
understand how the TCR:pMHC interaction impacts T cell
responses. The relationship between TCR afﬁnity and T cell
activation is complex, but in general, T cell functional activity
correlates with TCR binding afﬁnity for pMHC (13–19).
However, there are important nuances to this general theme.
For example, tumor-associated antigens may be skewed towards
lower-afﬁnity clones due to thymic negative selection (20, 21),
even the lowest-afﬁnity TCRs can induce T cell proliferation,
cytokine production and memory formation (19, 22). On the
other end of the spectrum, high afﬁnity TCRs have been shown
to enhance immune responses in some cases (23) and attenuate
responses in others (24–29), with some reports showing evidence
of an afﬁnity threshold beyond which increased afﬁnity does not
impact the magnitude of the response (17, 18). An additional
consideration is that even when high-afﬁnity TCRs are capable of
heightened cytotoxicity and tumor control, these TCRs may be
predisposed to autoimmunity (30). Thus, the optimal afﬁnities
for TCRs engineered against tumor-speciﬁc peptides may lie
within a low or intermediate afﬁnity (14, 24–26, 30–36). As most
afﬁnity studies to date have focused on CD8+ TCRs, CD4+ T cell
afﬁnity thresholds are less well characterized.
The role of the CD4 coreceptor is an important consideration
when associating TCR-pMHCII afﬁnity to CD4 + T cell
activation. CD4 binds to MHCII as part of the TCR complex
and contributes to proximal TCR signaling, proving especially
critical for T cell function when cognate pMHC ligands are
limiting (<30 complexes) (37). TCR signaling dependence on
CD4 is affected by the quality of TCR:pMHCII interaction and is
unnecessary upon stimulation with optimal ligands (38). Thus,
CD4 may be restricted to improving the TCR dwell time on
pMHCII for lower afﬁnity interactions (39). As CD4+ TCRs can
function in natural killer cell lines without CD4 (40), CD4 may
not have as great of an effect on T cell activation as CD8,
particularly with high afﬁnity TCRs.
To determine how TCR-pMHCII afﬁnity and CD4 coreceptor
interactions affect CD4 + T cell activation, we examined
activation of the CD4 transgenic murine T cells LLO118 and
LLO56 that are stimulated by the same Listeria monocytogenes
epitope. These TCRs differ by 15 amino acids and recognize the
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MATERIALS AND METHODS
Library Construction
Yeast display allows for the external presentation and screening
of large libraries of genetically altered proteins (43, 44). Single
chain T cell receptor (scTCR) contain linked variable TCR a and
b domains but lack constant domains and any signaling
domains. The scTCR constructs for LLO56 (residues 1–116)
and LLO118 (residues 1–120) (Invitrogen) consist of the mature
Vb domain, a 13-aa linker (DAKKDAAKKDDAS) (50), followed
by the mature Va domain (LLO118 residues 1–112 or LLO56
residues 1–113), and an N-terminal HA tag (PYDVPDYA). To
display scTCRs on yeast, the constructs were placed in pCT302
(NheI and BglII) (Addgene plasmid # 41845; http://n2t.net/
addgene:41845; RRID : Addgene_41845) (51). Stability clones

2

January 2021 | Volume 11 | Article 561889

Johnson et al.

CD4 Inhibits High Afﬁnity TCR Activation

were selected from scTCR transcripts replicated by error-prone
PCR (Standard Taq, New England BioLabs, B9014S) (44).
Afﬁnity libraries were generated using site directed mutagenesis
of 5 amino acids in the CDR3b region and splicing by overlap
extension (SOE) PCR (44, 52) using LLO118 and LLO56 speciﬁc
primers (Q5 High Fidelity DNA Polymerase, New England BioLabs
M0491) (Supplementary Materials).
To generate yeast libraries, 150 ml cultures of growth phase
EBY100 yeast were collected and washed twice with 50 ml icecold water and once with ice-cold electroporation buffer (1 M
Sorbitol/1 mM CaCl2) then resuspended in 0.1 M LiAc/10 mM
DTT and incubated at 30°C and 225 rpm for 30 min (53). Cells
were washed with 50 ml electroporation buffer, resuspended in
200 µl electroporation buffer and aliquoted with digested
pCT302 backbone (NheI and BglII, 1,250 ng) and inserted
(6,250 ng) into 0.2 mm gap cuvettes then electroporated (2.5
kV and 25 µF). Cells were allowed to recover for 1 h in 4 ml 1 M
sorbitol:YPD media (1:1) and were resuspended in SD-CAA
media and incubated for 2–3 days at 30°C before quantiﬁcation.
Stability and afﬁnity library sizes ranged from 1.1x107 to 1.9x109.

stained with 100 µl of various concentrations of LLO190-201/I-Ab
tetramer (0.152 nM to 12.16 nM) for 1.5 h at room temperature
and quantiﬁed via ﬂow cytometry. Tetramer binding was
assessed as MFI of positive population and normalized to the
highest recorded MFI using FlowJo. KD was deﬁned as 50%
maximum binding concentration (55).

Stability Clone Selection

The following protocol was modiﬁed from Garcia et al[61].
Brieﬂy, scTCR constructs were cloned into pET28a (Novagen)
using NcoI and SacI restriction sites. Constructs were expressed
in BL21 T7 Express E. coli (New England Biolabs) and protein
expression was induced for 4 h (0.4 mM isopropyl b-Dthiogalactoside). Cells were lysed with 1 mg/ml lysozyme
(ThermoFisher Scientiﬁc), 5 mM MgCl2, 1 µl/ml DNase I
(Promega), 1% Triton-X 100, and 10 mM dithiothreitol
followed by two rounds of soniﬁcation (Branson Digital
Sonifer) for 1 min at 0.5 s alternations at 40% power. Fifty to
200 mg of inclusion body slurry was dissolved in 1 ml of 7M
GnHCl and 10 mM beta-mercaptoethanol. Four hundred ml of
2 M GnHCl, 50 mM Tris-HCl, 2mM GSH, 0.2 mM GSSG, and
0.1% NaAz were dripped into dissolved inclusion bodies for 2–4
h at 4°C. Then 2–2.5 L of 200 mM NaCl, 50 mM Tris-HCl, and
0.1% NaAz were dripped for 24 h (1.5 ml/min speed) at 4°C.
Following an additional 24 h spinning at 4°C, the refolded TCR
solution was vacuum ﬁltered with 0.22 µm PES membranes
(Olympus Plastics), and then concentrated in an Amicon 8400
unit (Ultracel 10 kdal Ultraﬁltration Discs) under 55psi N2. Once
the volume was reduced to 50–100 ml of refolded scTCRs, the
samples were again ﬁltered with 0.45 µm CA-membrane and GF
preﬁlter syringe ﬁlter and puriﬁed by FPLC (AKTAstart) on a
HisTrap column (GE Life Sciences). Puriﬁed scTCRs were
concentrated using Amicon centrifugal ﬁlters (Ultra 4 10k) and
quantiﬁed by Pierce BCA Protein Assay kit (Thermo Scientiﬁc).

Tetramer Decay
Half-life (t1/2) was determined by staining 3x106 cells of each
afﬁnity clone with 6.5 µg/ml of tetramer for 1.5 h at room
temperature (56). Samples were washed three times in PBS 1%
BSA to remove excess tetramer. Following an initial timepoint
measurement, 90 µl of 0.1 µg/ml or 1 µg/ml anti-mouse MHC
class II (I-A/I-E) (clone: M5/114.15.2, eBioscience) was added
and the decrease of tetramer binding was quantiﬁed at various
time points (2, 5, 10, 15, 20, 30, 45, and 60 min) by placing 10 µl
of cells into 90 µl of buffer and running immediately on the
ﬂow cytometer.

scTCR Expression, Refolding, and
Puriﬁcation

Libraries calculated to have at least 10 copies of each clone were
placed in 5 ml SG-CAA media for 36–48 h to induce scTCR
expression (54). To select stability clones, yeast libraries were
incubated with either 2 µg/ml anti-mouse TCR Va2 or antimouse TCR Vb2 phycoerythrin-conjugated antibodies
(BioLegend, clone B20.1 and B20.6, respectively) in 5 ml PBS
1% BSA for 2 h at 4°C, washed with 15 ml PBS 1% BSA and
stained with 50 µl anti-PE MicroBeads in 2 ml PBS 1% BSA
(Millitenyi 130-048-801) for 20 min at 4°C. Labeled clones
expressing properly folded Va or Vb were positively selected
in magnetic LS columns (Millitenyi 130-042-401). Selected cells
were grown in 3 ml SD-CAA media (48 h) before induction in
SG-CAA (36–48 h). Each library was subjected to three rounds of
growth and sorting, and the most stable clone identiﬁed via ﬂow
cytometry (BD Accuri C6). Stability clones were used as
templates for subsequent stability or afﬁnity libraries.

Afﬁnity Clone Selection
To select afﬁnity clones, induced yeast libraries were
incubated with tetramer (LLO 1 90 -2 01 /I-A b ) (I-A(b)CC
(NEKYAQAYPNVS), NIH 22201), and sorted like stability
clones. To isolate high afﬁnity clones, libraries were exposed to
an increasingly strict temperature and incubation regimen.
Initially, libraries were subjected to high concentrations of
tetramer (13.0 µg/ml), high temperatures (37°C), and long
incubation times (3 h), and in later rounds, combinations of
lower tetramer concentrations (3.25 µg/ml), lower temperatures
(RT or 4°C), and shorter incubation times (1 h) were used to
isolate the clones with highest afﬁnity. Each library was column
sorted three times. Isolated clones with increased tetramer
binding were identiﬁed via ﬂow cytometry (BD Accuri C6).

Bio-Layer Interferometry (BLI)
BLI experiments were performed with an Octet RED96.
Streptavidin (SA) biosensors (Forté Bio) were hydrated and
equilibrated in 1x HEPES buffered saline (HBS, 50 mM
HEPES, 150 mM NalCl, pH 7.2), 2mM CaCl2, 1 mM MgCl2, 1
mg/ml milk, 0.1% Tween, and 0.02% NaN3. SA sensors were
loaded with 2.0 µg/ml biotinylated LLO190-201/I-Ab monomer or
DQB187-101/I-Ab monomer to 1.0–2.0 nm. Loaded biosensors
were equilibrated in assay buffer until baseline was achieved.

Tetramer Dissociation
Each afﬁnity and stability clone KD was determined through
tetramer dissociation (55). Aliquots of 1x106 induced cells were
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mixed with 1 ml of 1x106 58-/- CD4- or 58-/- CD4+ cells in a 6well plate and spinfected for 2 h at 30°C at 1,000 G (acceleration
6, brake 2). After 48 h recovery, clones Vb2, Va2, and GFP+
expression was checked by ﬂow cytometry. Clones with under
85–90% GFP expression were sorted 1–3 times with magnetic LS
columns (Miltenyi Biotec, 130-042-401) using 10 µl Vb2-PE
antibodies and 10 µl anti-PE MicroBeads (Miltenyi Biotec, 130048-801) per manufacturer speciﬁcations. Clones were checked
for TCR expression after each sort round. CD4T+ and CD4T+
Dbind (60) were cloned into pMIGII (MfeI/XhoI) and
retrovirally transfected into existing 58-/- CD4- ﬂTCR and
TCR-SCS clones and sorted for >95% CD4 expression (CD4
PE-Cy7, GK1.5, Biolegend) by ﬂow sorting (BD FACSAria II).
Twenty-ﬁve thousand cells were stained with respective antibodies
or tetramer for all afﬁnity and stability measurements and
measured with ﬂow cytometry (BD Accuri).

scTCR association was probed in wells with assay buffer (stability
clones 2, 1, 0.5, 0.25, 0.125, 0.061 µM; afﬁnity clones 800, 400,
200, 100, 50, and 25 nM, or 20, 10, 5, 2.5, 1.25, and 0.625 nM)
with a blank reference-subtraction well for 400–600 s. Ideal
concentration range spanned one log above and below the KD
where possible; however, this range had to be optimized
depending on the sensitivity of the assay, and on the amount
of protein available. Matching of sample and baseline imidazole
and milk concentrations (through serial dilution of sample buffer
into baseline wells) was critical for detection of scTCR binding.
Blocking with bovine serum albumin increased non-speciﬁc
binding while milk efﬁciently blocked NSB. Dissociation was
observed in baseline assay buffer (600–1,200 s). Assays were run
at 30°C with a plate shake speed of 1,000 rpm.
Data was collected at 5 Hz, using 20-point signal averaging
and analyzed using custom kinetic analysis. Due to non-speciﬁc
binding at the later stages of the association and dissociation
steps, KD was calculated by extracting and selecting the data
points from the initial association to determine kobs (2–100 s
depending on the afﬁnity of the constructs), plotting
concentration vs rate, and then plotting those slopes against
scTCR concentration and estimating kassoc from the slope. kdissoc
is the slope of concentration vs rate of the dissociation step data
(2–100 s depending on the afﬁnity of the constructs). KD was
determined by dividing kdiss/kassoc and t1/2 = ln2/kD.

T Cell Hybridoma Peptide-Speciﬁc
Activation and IL-2 Measurement
2.8x104 T cell hybridoma clones were incubated with 2.8x105
splenocytes (1:10) isolated from BL6.C57 mice with varying
amounts (10-8 M to 10-3 M) of peptide (LLO190-205, GenScript)
in 75 µl 58-/- media in 96 well plate for 24 h. IL-2 production was
measured using an IL-2 ELISA kit (KIT) and measured on a
microplate reader. This study was approved and carried out in
accordance with principles of the Basel Declaration and
recommendations of Brigham Young University’s Institutional
Animal Care and Use Committee (IACUC protocol #18-0708).

Cell Culturing
All 58-/- T cell hybridoma cell lines were cultured in RPMI 1640,
10% FBS, 2g/L NaHCO3 (23.8 mM), HEPES (4.2mM), L-glutamine
(3.24 mM), 1% Penn-strep and split 1:5 or 1:10 every 2–3 days.
Platinum Ecotrophic cells (Plat E) were cultured in DMEM, 10%
FBS, 1% pen-strep, 1 µg/ml puromycin, and 10 µg/ml blasticidin
and split 1:4 every other day.

Statistical Analysis
Statistical analysis was performed via one-way ANOVA with
Tukey’s multiple comparison test (p < 0.05 was signiﬁcant, no
alpha adjustments required). Half-life (t1/2) was determined by
linear regression between time point 0 and the time point where
no tetramer binding was detected (56). To determine the KD, we
ﬁt the data with a non-linear curve, based on one site-speciﬁc
binding kinetics (55). EC50 was determined with Sigmoidal, 4PL,
X is log(concentration) least squares ﬁt. Standard deviation is
reported for each value. All analyses were conducted in
GraphPad Prism.

Retroviral Transduction of T Cell
Hybridomas
Afﬁnity mutations were cloned into four possible constructs: full
length TCRs (ﬂTCRs), and three TCR-single chain signaling
formats based on chimeric antigen receptor (CAR) formats
(second generation 4-1BB and CD28 CARs, and third generation
4-1BB/CD28 CAR). Inserts were cloned into pMSCV-IRES-GFP II
(pMIGII) (Addgene plasmid # 52107; http://n2t.net/
addgene:52107; RRID : Addgene_52107) using MfeI and XhoI
(GenScript) (57). All constructs were led by a Kozak
sequence and either Va2 signal peptide (MDKILTASFLLL
GLHLAGVSGQ) and an additional Vb2 signal peptide
(MWQFCILCLCVLMASVATD) for ﬂTCRs or high afﬁnity M33
3rd gen CAR signal peptide (MLLALLPVLGIHFVLRDAQA) for all
TCR-SCS CAR constructs (58). ﬂTCR constructs have a P2A
cleavage domain (GSGATNFSLLKQAGDVEENPG) (59)
between Ca2 and Vb2 domains. All TCR-SCS and ﬂTCR were
linked to GFP by an IRES domain and GFP expression mirrors TCR
construct expression in cell lines.
Vectors were transfected into Plat E packaging cells grown
overnight in 6-well plates with TransIT-VirusGEN (Mirus, MIR
6703). Forty-eight hours later, 1 ml of viral supernatant was

Frontiers in Immunology | www.frontiersin.org

RESULTS
Yeast Displayed TCR Panel Has Varied
Afﬁnities
Murine transgenic helper T cells LLO56 and LLO118 bear TCRs,
which recognize the same naturally occurring Listeria
monocytogenes peptide (LLO190-205) presented on MHCII (IAb). The LLO56 and LLO118 TCR bind cognate pMHC with
similar afﬁnity (27.4 µM and 28.3 µM, respectively), yet have
unique primary and secondary responses to TCR stimulus
(summarized in Supplemental Table S1) (41, 42). LLO56 and
LLO118 differ from each other by 15 amino acids located in the
complementarity determining regions (CDR) CDR3b (amino
acids 96–108, 111, 116, 118), CDR2b (aa52), and CDR3a (aa93)
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hotspots (Supplemental Figure S1). To generate afﬁnity
mutants, ﬁve amino acids in the stability mutants LLO56low
and LLO118low CDR3b region were mutated by site directed
mutagenesis and selected for improved binding afﬁnity for
LLO 190-201 /I-A b tetramers by magnetic column sorting.
Increases in scTCR afﬁnity cannot be explained by increases in
scTCR expression, as HA and TCRa and TCRb antibody
binding remained the same across each experiment (Figure
1B). Additionally, none of the isolated stability or afﬁnity
mutants bound signiﬁcantly to a non-target peptide tetramer
(DQB187-101/I-Ab), indicating that the increase in tetramer
binding is due to peptide-speciﬁc binding and not increased
afﬁnity for I-Ab alone (Figure 1D). Afﬁnity mutant LLO56int

regions (Supplemental Figure S1). To further elucidate the
effects of TCR-pMHCII afﬁnity on CD4+ T cell activation, the
variable regions of LLO56 and LLO118 (Figure 1A) were used as
templates for generating a panel of single-chain TCRs (scTCRs)
with low (wild type), intermediate, and high afﬁnities. scTCR
libraries generated by random mutagenesis and expressed via
yeast surface display (Figure 1B) were selected for protein
folding stability through magnetic column sorting (Figure 1C).
scTCR expression levels vary according to yeast cell cycle stage and
can result in multiple peaks. The left peak is the non-displaying
fraction and there can be intermediate and high displaying yeast
(61). Vb2 stability mutations were conserved between constructs
while Va2 stability mutations clustered in known stability

B

A

C

D

E

FIGURE 1 | LLO118 and LLO56 stability and afﬁnity maturation by yeast display. (A) Schematic of single-chain TCR (scTCR) which includes TCR a and b variable
domains (Va and Vb) spliced from TCR constant domains and connected with a 13 amino acid linker. Aga-2 is the yeast mating protein that displays the scTCR on
yeast cell membrane. Each construct contains an HA tag for antibody detection. (B) Schematic of a scTCR displayed on the cell surface via yeast display. The yeast
mating protein Aga1 binds to the Aga2-scTCR fusion protein and enables the display of these proteins on the cell surface. Large scTCR libraries can be generated,
stained with antibodies or peptide-MHC tetramers, and yeast clones containing scTCRs with improved stability or afﬁnity characteristics can be identiﬁed and
selected. (C) Wild type LLO118 and LLO56 were engineered for improved stability and higher afﬁnity by yeast surface display. Clones with stability mutations were
selected for using monoclonal anti-Va or anti-Vb antibodies. The surface displayed constructs were then selected for improved afﬁnity using the peptide MHC
tetramer LLO190-201/I-Ab. Staining of wild type clones LLO56WT and LLO118WT (ﬁrst and fourth columns), stability clones LLO56low and LLO118low (second and ﬁfth
columns), intermediate afﬁnity clones LLO56int and LLO118int (third and sixth columns) and high afﬁnity clone LLO118high (seventh column) is shown. Stains include
antibodies against the HA epitope (ﬁrst row), Va2 (second row), and Vb2 (third row), or LLO190-201/I-Ab pMHCII tetramer (fourth row). Gray-ﬁlled histogram represents
cells-only control. Histograms are representative of n >3 experiments. (D) Afﬁnity clones were incubated with saturating amounts of non-target tetramer (DQB187-101/
I-Ab). Histograms compare cells only (black clear) with afﬁnity clones (colored, shaded). (E) Vb2 CDR3 mutations that confer increases in afﬁnity. CDR3b regions are
hypervariable; therefore, gaps mark the length of other known Vb2 CDR3b regions. First round of afﬁnity selection (light gray) for all afﬁnity clones while second round
of afﬁnity selection (dark gray) applies only to LLO118high.
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ﬁve additional CDR3b mutations (Figure 1E). While LLO56int
and LLO118high mutants were used as templates for mutant
libraries of the complementary determining region 3 of the a
chain (CDR3a), no further clones with increased-afﬁnity for
LLO190-201/I-Ab tetramer were isolated, suggesting that CDR3b is
primarily responsible for LLO190-201 peptide interactions for

with four CDR3b mutations (Figure 1E) bound LLO190-201/I-Ab
1.5 log better than stability mutant LLO56low (Figure 1C).
Afﬁnity mutant LLO118high bound to the LLO190-201/I-Ab
tetramer 1.0-log better than afﬁnity mutant LLO118int and 2.5log better than stability mutant LLO118 low (Figure 1C).
LLO118int had three CDR3b mutations and LLO118Ahigh had

A
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E

F

G

H

FIGURE 2 | Avidity and afﬁnity measurements of scTCRs. (A) To estimate avidity KD, afﬁnity clones presented by yeast were incubated with various concentrations
of LLO190-201/I-Ab tetramer (1.52–50 nM) and 50,000 events were collected via ﬂow cytometry. Grey dotted lines represent non-linear, one site-speciﬁc binding
analysis of tetramer binding measurements used to estimate KD for LLO56int (red), LLO118int (blue), and LLO118high (dark grey) (n = 3 experiments). (B) Percent of
cells bound by tetramer for each afﬁnity clone. LLO56low had signiﬁcantly lower binding than LLO56int (0.75 ± 0.3% to 12.6 ± 3.4%, p = 0.0193) while LLO118low
(1.1 ± 0.5%) was signiﬁcantly lower than LLO118int (24.5 ± 2.9%) and LLO118high (43.3 ± 8.9%) (p < 0.0001 and p < 0.0001, respectively) and LLO118int was
signiﬁcantly lower than LLO118high (p = 0.0004). To determine t1/2, yeast displayed afﬁnity clones were incubated with (C) 1 M and (D) 0.1 M LLO190-201/I-Ab
tetramer. Following an initial measurement, 1.0 µg/ml anti-mouse MHC class II (I-A, I-E) monoclonal antibody was added and tetramer binding measured at each
time point by ﬂow cytometry. t1/2 was estimated as the time it took to reach 50% MFI modeled by non-linear dissociation one phase exponential decay (dotted light
grey lines) (n = 3 experiments). (E) A graphical depiction of range of afﬁnity clones. To estimate TCR afﬁnity, scTCRs were secreted by E. coli, chemically refolded,
and incubated with streptavidin sensors loaded with biotinylated LLO190-201/I-Ab monomer using BLI. No binding was observed between scTCRs and streptavidin
biosensors in the absence of LLO190-201/I-Ab loading (n = 3–6 independent measurements). (F) kobs is the linear slope of nm vs time. (G) kassoc is the linear slope of
kobs vs scTCR concentration. (H) kdiss is the exponential slope of dissociation nm vs time. *<0.05, ***<0.001, ****<0.0001.
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TABLE 1 | Comparison between scTCR clones avidity (Tetramer) and afﬁnity Kd (Bio-layer Interferometry).
Tetramer (Avidity)

LLO56low
LLO56int
LLO118low
LLO118int
LLO118high

Bio-layer Interferometry (Afﬁnity)

t1/2 (m)

r

2

2

KD

r

1

0.97

39.2 ± 46.7 nM

0.82

1
165

0.97
0.76

44.8 ± 52.3 nM
7.33 ± 1.37 nM

0.96
0.87

-1 -1

kassoc (M s )
18300
27600
10200
20000
73000

these speciﬁc TCRs. It is important to note that the stability
clones initially isolated from yeast libraries relied on a frameshift
mutation at the stop codon that added 19-amino acids from
the yeast expression vector to the carboxy end of Va2
(RSDNNSVDVTKSTLFPPYF). While LLO56low and LLO56int
successfully retained stability and afﬁnity gains without the 19
amino acids, several attempts to create new LLO118 stability and
afﬁnity clones without the additional amino acids were
unsuccessful. Therefore, the stabilizing 19 amino acids were
maintained for LLO118 clones. Other studies have utilized
TCR formats that express constant domains in order to
maintain scTCR folding while adding additional afﬁnity
mutations to the TCRs, therefore this observation was not
unexpected (62–64).
The multivalent binding avidity of each clone was determined
by LLO190-201/I-Ab tetramer titration (150 pM–15.00 nM) of
scTCR expressed on yeast (Figure 2A). Avidities ranged from the
highest clone LLO118high (7.30 nM), to intermediate avidity
clones LLO56 int (39.20 nM) and LLO118 int (44.80 nM)
(Figures 2A, B and Table 1). Stability clones LLO56low and
LLO118low were excluded from these analyses because binding
was undetectable even at the highest concentrations of LLO190b
201/I-A tetramer (Figure 2B). Tetramer decay analysis of clones
displayed on yeast determined that the multivalent half-life for
LLO118high (t½ = 165 min, r2 = 0.76) was 165-times longer than
LLO118int and LLO56int (t½ = ~1 min each, r2 = 0.97 each)
suggesting that the increased avidity of LLO118 high is
predominantly due to a lengthened off-rate (Figure 2C). A
second round of tetramer decay with lower levels of MHC
inhibiting-antibody better resolved the half-lives of LLO118int
(t½ = 6.7 mins, r2 = 0.97) and LLO56int (t½ = 3.5 mins, r2 = 0.98)
(Figure 2D), indicating that LLO118int has a longer dissociation
rate than LLO56int. The resulting panel of TCRs provides a range
of tetramer avidities ranging from high to low (Figure 2E).
While tetramer avidity measurements may be more
physiologically relevant as multiple TCR-pMHCs interact
simultaneously during T cell activation, TCR-pMHC afﬁnity
measurements provide a standard measurement to compare
between TCR systems. Therefore, TCR:pMHC afﬁnity was
measured by quantifying the interaction of monomeric
refolded scTCR with monomeric LLO190-201/I-Ab via bio-layer
interferometry. Due to non-speciﬁc binding at the later stages of
the association and dissociation steps, the KD was calculated
manually by extracting the data from the early measurements;
k obs slopes ((Figure 2F) were plotted against scTCR
concentration (Figure 2G) and kassoc estimated from the slope.
kdiss is the slope of dissociation graphs (Figure 2H). KD was
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± 7000
± 3000
± 1500
± 1400
± 8600

kdissoc (s-1)

t1/2 (s)

KD

0.053 ± 0.020
0.018 ± 0.0007
0.043 ± 0.004
0.025 ± 0.007
0.002 ± 0.0007

14.5 ± 5.7
422.0 ± 163.1
16.1 ± 1.3
28.8 ± 7.4
460.0 ± 176.8

2.9 ± 0.7 µM
66.2 ± 39.8 nM
4.3 ± 0.7 µM
1.3 ± 0.3 µM
20.0 +/- 13.9 nM

determined by dividing kdiss/kassoc. LLO118high (20.0 ± 13.9 nM)
KD was 215-fold higher than LLO118low (4.3 ± 0.7 µM) (Table
1). Intriguingly, while LLO118 int and LLO56 int avidity
measurements were similar, their afﬁnity measurements were
markedly different (20-fold). LLO118int (1.3 ± 0.3 µM) was only
3-fold higher afﬁnity than LLO118low and LLO56int (66.2 ± 39.8
nM) was 43-fold higher than LLO56low (3.8 ± 1.3 µM) (Table 1).

Construct Format Impacts Surface
Expression and pMHCII-Afﬁnity
Independently
To quantitatively assess the effects of TCR-pMHC afﬁnity, CD4,
and construct format on helper T cell activation, TCR constructs
were retrovirally transduced into murine T cell hybridomas, 58-/CD4- (CD4-) and 58-/- CD4+ (CD4+), which do not express
endogenous TCRs. 58-/- T cell hybridoma cell lines have been a
useful cell line for examining TCR kinetics and IL-2 production
prior to primary cell line observations (47, 49, 65, 66). LLO56low
and LLO56int were placed in the three TCR-SCSs formats, and
LLO56WT and LLO56int were placed in ﬂTCR constructs without
stability mutations (Figures 3A, B, Supplemental Figures S2–
S5). Because of the necessity of the additional 19 amino acids,
LO118low, LLO118int, and LLO118high afﬁnity changes were not
transferred to ﬂTCR constructs. LLO118low, LLO118int, and
LLO118high were placed in three TCR-SCSs formats based on
commonly used second and third generation chimeric antigen
receptor (CAR) formats (Figures 3A, B, Supplemental Figures
S2–S4). The transduced cell lines were sorted with anti-Vb2
antibodies via magnetic column selection for >85% GFP+ and
TCR expression (Figure 3C).
TCR stable surface expression varied by individual constructs.
As assessed by Vb2 expression, ﬂTCR constructs were less stably
expressed than all TCR-SCS constructs perhaps due to CD3
subunit availability, while TCR-SCS CD28 constructs were the
most stably expressed format for both LLO56 and LLO118
constructs (Figure 3D). While most construct expression was
equitable between CD4- and CD4+ cell lines, TCR-SCS 4-1BB
constructs had the most expression variability between
constructs as CD4 expression destabilized LLO118low and
LLO118int TCR-SCS 4-1BB expression (p = 0.0018 and p =
0.0429, respectively) (Figure 3D). CD4- LLO118high 4-1BB
constructs were less stable than CD4- LLO118low 4-1BB and
LLO118int 4-1BB (p = 0.0030 and p = 0.0002, respectively)
(Figure 3D). CD4+ LLO118high 4-1BB was also less stable than
either LLO118low or LLO118int (p = 0.0285 and p = 0.0493)
(Figure 3D). Overall CD4 expression did not signiﬁcantly
destabilize 3rd gen constructs except LLO118low (p = 0.0401)
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A

B

C

D

FIGURE 3 | TCR-SCS and ﬂTCRs are stably expressed in CD4- and CD4+ T cell hybridomas. (A) Diagrams depicting the ﬂTCR formats and three TCR-SCS
formats in the cell membrane. All TCR-SCS constructs have signaling coreceptor CD3 in addition to the signaling domains of coreceptors CD28 and/or 4-1BB.
(B) TCR constructs are produced from a bicistronic IRES-GFP vector and GFP expression mirrors TCR construct expression in cell lines. In addition to the P2A
cleavage domain, TCR-SCS formats rely on TCR M33 signal peptide (67), whereas the ﬂTCR has dedicated signal peptides for a2 and b2 to increase localization of
both chains to the surface. The CD8 hinge acts as an intermembrane domain. (C) An example of TCR-SCS expression in CD4- (top) and CD4+ (bottom) T cell
hybridoma lines after magnetic column sorting with anti-Vb2 monoclonal antibodies (LLO118high TCR-SCS CD28). Initial retroviral transfections ranged from 11 to
85% efﬁciency. Grey peaks in GFP histograms represent a GFP- cells-only control. GFP+ cells were gated for CD4 expression and Va2 and Vb2 expression.
Representative of n = 3 measurements of 20,000 cells via ﬂow cytometry. (D) Mean ﬂuorescent intensity (MFI) of Vb2 was used as a proxy for stable expression of
constructs. Constructs were expressed in CD4- (solid bars) and CD4+ (hatched bars) T cell hybridomas. Representative of n = 3 measurements of 20,000 cells via
ﬂow cytometry. *<0.05, **<0.01, ***<0.001.

and LLO56int where CD4 stabilized VB2 expression (p = 0.0109)
(Figure 3D). GFP expression does not correlate with expression
differences of the constructs for each format between CD4- and
CD4+ expression nor expression differences between TCR
(Supplemental Figures S6).
Tetramer titrations were used to approximate the avidity of each
ﬂTCR or TCR-SCS construct. Intriguingly, the intracellular format
strongly inﬂuenced the avidity of each intermediate and high
afﬁnity TCR construct (Figure 4A). There is no clear link across
all clones between stable Vb2 expression and construct avidity,
although the most stable constructs—TCR-SCS CD28—did have
the highest apparent avidity (LLO56int and LLO118high) (Figure
4A). Overall, CD4 expression (dotted lines) did not affect the
avidity of the constructs, excepting LLO118int and LLO118high 3rd
gen constructs where CD4 lessened and heightened avidity,
respectively (Figure 4A). The MFI measured for each clone at
10-8 M (a non-saturated concentration) were used to compare
avidity differences between afﬁnity clones. LLO56 4-1BB, 3rd gen
and ﬂTCR constructs had no signiﬁcant differences between
LLO56low and LLO56int (Figure 4B). This may be due to the
small afﬁnity differences between LLO56low and LLO56int as
measured in tetramer and bio-layer interferometry assays.
However, LLO118 3rd gen constructs also did not show afﬁnitydependent avidity changes, thus intracellular signaling domains
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may also affect the avidity of extracellular scTCRs. There were
signiﬁcant avidity differences for LLO118 4-1BB clones; CD4LLO118high 4-1BB had signiﬁcantly better avidity than its cognate
CD4+ pairing (p = 0.0004), and was also signiﬁcantly higher than
CD4- LLO118low and LLO118int 4-1BB (p = 0.0003 and p = 0.0092,
respectively) (Figure 4B). Additionally, TCR-SCS CD28 constructs
for both LLO56 and LLO118, which are the most stably expressed
constructs (Figure 3D), showed increased MFI by increasing TCR
afﬁnity (Figure 4B). LLO56int CD28 had signiﬁcantly greater
avidity than LLO56low CD28 (CD4- p = 0.0122 and CD4+ p=
0.0086), as did LLO118high CD28 compared to LLO118low (CD4p = 0.0129 and CD4+ p= 0.0113) (Figure 4B). IL-2 production is
not correlated with GFP intensity (Supplemental Figure S6). Taken
together, while there is no systematic correlation, this data suggests
that construct stability may inﬂuence avidity measurements, as
CD28 clones had the highest stability and avidity, and conﬁrms
that generally, CD4 does not affect perceived avidity.

CD4 Inhibits High Afﬁnity TCR IL-2
Production
To assess the effects of TCR-pMHCII afﬁnity, CD4 expression,
and format on T cell activation we measured IL-2 expression in
response to increasing agonist peptide concentrations. As
anticipated, LLO56low ﬂTCR IL-2 production improved with
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A

B

FIGURE 4 | TCR-pMHCII avidity is affected by construct format. (A) ﬂTCR or TCR-SCS expressing cell lines were incubated with varying amounts of LLO190-201/IAb tetramer (10-7 M to 10-12 M) at room temperature for 2 h. Each TCR-format pair expressed in CD4- cell lines (solid lines) and CD4+ cell lines (dotted lines) have
similar afﬁnities, whereas each unique construct format alters avidity of a single TCR. Representative of three independent measurements of 20,000 cells via ﬂow
cytometry. (B) Tetramer MFI measurements of 10-8 M separated by TCR and format where CD4- cell lines (solid bars) and CD4+ cell lines (hashed bars) are paired.
*<0.05, **<0.01, ***<0.001.

production (Figures 5F, G). As noted in low afﬁnity scTCR
clones (LLO56low 3rd gen and CD28, and LLO118low 3rd gen)
(Figures 5B, C, F), CD4+ and CD4- clones may also respond
uniquely across antigenic concentrations, however this is likely
an artifact due to variability or the limits of detection.
While CD4 promoted the activation of all low afﬁnity clones,
it unexpectedly suppressed IL-2 production for all intermediate
and high afﬁnity constructs (Figure 5). The magnitude of IL-2
suppression is greatly dependent on whether the construct was a
ﬂTCR or TCR-SCS construct. For example, while LLO56low
ﬂTCR IL-2 production was assisted by CD4 expression,
LLO56int ﬂTCR IL-2 production was reduced 2.2-fold (p =
0.0707) at 10-3 M peptide stimulation (Supplemental Figure
S7). In contrast, only one TCR-SCS had such a mild IL-2
reduction. CD4+ LL056int 4-1BB IL-2 production was reduced
by 2.5-fold (p = 0.1551) (Supplemental Figure S7). The IL-2
production for the other intermediate and high afﬁnity TCR-SCS

CD4 expression, but CD4 expression unexpectedly reduced IL-2
production for LLO56 int ﬂTCR (Figure 5A). Despite the
inconsistent role of CD4, ﬂTCRs produced signiﬁcantly more
IL-2 at all afﬁnity levels (Figure 5A) and were at least 1-log fold
more sensitive to peptide than all TCR-SCSs (Figures 5B–D). IL2 production for CD4- clones rose with increased TCR afﬁnity
for most constructs except 3rd gen constructs; LLO56int 3rd gen
failed to produce more cytokines than LLO56low 3rd gen (Figure
5B) and LLO118high 3rd gen that produced less IL-2 than
LLO118int 3rd gen (Figure 5C). This pattern of uneven gains
across afﬁnity and base TCR was also observed for 4-1BB
constructs (Figures 5D, E); while LLO56 4-1BB did see gains
across afﬁnity (Figure 5D), LLO118 4-1BB constructs had
limited afﬁnity gains across the afﬁnity gradient (Figure 5E).
CD4- LLO56int CD28 and CD4- LL0118high CD28 produced
more IL-2 than other TCR-SCS constructs which suggested
that their heightened stable expression may promote IL-2
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FIGURE 5 | CD4 inhibits IL-2 production of intermediate and high afﬁnity TCRs. CD4- (solid lines) and CD4+ (dotted lines) T cell hybridoma cell lines were incubated
with various concentrations of LLO190-201 peptide (10-8 M to 10-3 M) presented by BL6/C57 splenocytes for 24 h. IL-2 production was measured by ELISA. Each
sample was normalized by subtracting baseline IL-2 production from T cell hybridoma/splenocytes controls incubated without peptide. (A) LLO56 ﬂTCRs, (B) LLO56
3rd gen TCR-SCSs, (C) LLO118 3rd gen TCR-SCSs, (D) LLO56 4-1BB TCR-SCSs, (E) LLO118 4-1BB TCR-SCSs, (F) LLO56 CD28 TCR-SCSs, and (G) LLO118
CD28 TCR-SCSs. ELISAs run n = 3 times.

Lck Sequestration by CD4 Inhibits Some
TCR IL-2 Production

constructs was intermediately reduced for LLO56int CD28 (6.4fold, p = 0.0104), and severely reduced for LLO118int 3rd gen
(28.1-fold, p = 0.0004), LLO118int CD28 (21.2-fold, p = 0.0400),
LLO118high 3rd gen (16.5-fold, p = 0.0051), and LLO118high
CD28 (25.9-fold, p < 0.0001) (Supplemental Figure S7).
Peptide sensitivity, deﬁned as the lowest concentration where
IL-2 response exceeds baseline IL-2 production, was equitable
between CD4- and CD4+ for constructs LLO56int ﬂTCR, LLO56
3rd gen, and LLO56int 4-1BB (Figures 5A, D, Table 2), but
delayed 1-log fold for LL056int CD28 and at least 2-log fold for all
LLO118int and LLO118high constructs (Figures 5C, E–G, Table
2). This suggests that CD4 reduced peptide sensitivity for most
TCR-SCS constructs, possibly in a TCR-dependent manner.

Lck is an early proximal signaling kinase that colocalizes to the
cytoplasmic domain of CD4 (68, 69). If Lck is poorly recruited to
the TCR-pMHCII synapse, then T cell activation may be
diminished (49). We hypothesized that our high afﬁnity clones
may poorly recruit CD4-Lck to the immunological synapse,
decreasing activation, and therefore reducing IL-2 production
as observed in CD4+ intermediate and high afﬁnity clones. To
parse out the potential contributions of CD4-Lck sequestration,
CD4-MHCII interactions, and any CD4-dependent inhibition,
we expressed a selection of our ﬂTCR and TCR-SCS clones in
four 58-/- T cell hybridoma lines (49, 60). LLO56 TCR-SCS 3rd

TABLE 2 | Approximated peptide sensitivity for responding clones.
Peptide sensitivity
LLO56int

ﬂTCR
3rd gen
4-1BB
CD28

LLO118int

LLO118high

CD4-

CD4+

CD4-

CD4+

CD4-

CD4+

1.00E-06
1.00E-04
1.00E-05
1.00E-05

1.00E-06
1.00E-04
1.00E-05
1.00E-04

1.00E-04
1.00E-04
1.00E-04

ND
ND
ND

1.00E-04
1.00E-06
1.00E-05

ND
1.00E-04
ND

CD4 expression inhibited the production of IL-2 for most clones (marked in light red).
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FIGURE 6 | IL-2 production of intermediate and high afﬁnity clones is inﬂuenced by Lck sequestration, CD4-MHCII interaction, and CD4 presence. (A) CD4- has no
CD4 and Lck is spread ubiquitously along the inner membrane. (B) CD4+: wild type CD4 interacts with MHCII and the majority of Lck is sequestered to the
cytoplasmic tail of CD4. (C) CD4T+: mutant CD4T interacts with MHCII but does not sequester Lck which is spread ubiquitously along the inner membrane.
(D) CD4T+ D bind: mutant CD4T D bind does not bind to MHCII nor Lck (Lck is not sequestered to the cytoplasmic tail of CD4). ﬂTCR and SCS-TCR constructs
expressed in various T cell hybridoma clones [CD4- (red), CD4+ (green), CD4T+ (light blue), CD4T+ D bind (yellow)] were incubated with 10-3 M LLO190-205 presented
on Bl6.C57 splenocytes for 24 h. IL-2 production was measured by ELISA and normalized by subtracting IL-2 production without peptide for each clone-APC pair.
Histogram order: LLO56low (E) and LLO56int (F) ﬂTCRs; LLO56low (G), LLO56int (H), LLO118int (I), and LLO118high (J) CD28 TCR-SCS; LLO56low (K) and LLO56int
(L) 4-1BB SCS-TCR; LLO118int (M), and LLO118high (N) 3rd gen TCR-SCS. p-values were determined by multiple comparison one-way ANOVA for each graph are
from left to right LLO56int 4-1BB CD4- to CD4T+ (p = 0.0176), CD4+ to CD4T+ (p = 0.0036), and CD4T+ to CD4T+ D bind (p = 0.0138); LLO56int CD28 CD4- to
CD4+ (p = 0.0054), CD4- to CD4T+ (p = 0.0232), CD4+ to CD4T+ (p = 0.0002), CD4+ to CD4T+ D bind (p = 0.0245), and CD4T+ to CD4T+ D bind (p = 0.0153);
LLO118int 3rd gen CD4- to CD4T+ (p = 0.0027), and CD4T+ to CD4T+ D bind (p = 0.0077); LLO118int CD28 CD4- to CD4T+ (p = 0.0018), and CD4T+ to CD4T+ D
bind (p = 0.0010); LLO118high 3rd gen CD4+ to CD4T+ D bind (p = 0.0366); and LLO118high CD28 CD4- to CD4+ (p = 0.0010), CD4- to CD4T+ (p = 0.0221), CD4Tto CD4T+ D bind (p = 0.0021), and CD4+ to CD4T+ (p = 0.0117). *<0.05, **<0.01, ***<0.001, ****<0.0001.
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inhibited by CD4 Lck-sequestration, as CD4 + produced
signiﬁcantly less IL-2 than CD4T+ (p = 0.0162) (Figure 6F).
However, the more striking phenotype is LLO56int ﬂTCR CD4dependent inhibition, as IL-2 production is signiﬁcantly reduced
by the presence of CD4 in any form (Figure 6F). CD4- LLO56int
ﬂTCR cells produced signiﬁcantly more IL-2 than any clone
expressing CD4 (CD4+ p < 0.0001, CD4T+ p = 0.0019, and
CD4T+ Dbind p = 0.0002) (Figure 6F). Furthermore, CD4MHCII interaction was not a signiﬁcant contributor to
intermediate afﬁnity ﬂTCR IL-2 production as there was no
signiﬁcant change in IL-2 production between the CD4T+ and
CD4T+ Dbind clones (Figure 6F).
Low afﬁnity TCR-SCS clones LLO56low CD28 (Figure 6G)
and LLO56low 4-1BB (Figure 6H) were low IL-2 producers and
the role of CD4 was conﬂicting as all CD4 iterations inhibited IL2 production for 4-1BB but promoted IL-2 production for CD28
whether or not CD4 binds to MHCII. It was also difﬁcult to draw
conclusions about Lck-sequestration for low afﬁnity TCR-SCS
constructs due to low levels of IL2 production. Intermediate
TCR-SCS clones LLO56int CD28 (Figure 6I), LLO56int 4-1BB
(Figure 6J), LLO118int CD28 (Figure 6K), and LLO118int
3rd gen (Figure 6L) had a unique ubiquitous phenotype
comparable to the phenotype described for intermediate
afﬁnity ﬂTCR clones. IL-2 production was most reduced when
CD4 sequestered Lck in the CD4+ clones (Figures 6I–L).
However, intermediate TCR-SCS CD4T+ constructs produced
the most IL-2, indicating unrestricted Lck promotes the greatest
T cell activation (Figures 6I–L). CD4T+ Dbind compared to
CD4T+ signiﬁcantly reduced intermediate TCR-SCS construct
IL-2 production to CD4- levels suggesting that CD4-MHCII
binding supports IL-2 production for intermediate TCR-SCS
afﬁnity (Figures 6I–L). Noticeably, high afﬁnity LLO118 TCRSCSs followed the same inhibition patterns seen for LLO56int
ﬂTCR where inhibition by Lck sequestration and CD4 presence
was not signiﬁcantly affected by MHCII-CD4 binding (Figures
6M, N). Taken together, these data indicate that ﬂTCRs and
TCR-SCS have independent afﬁnity thresholds for the inhibitory
effects of Lck-sequestration and CD4-dependent inhibition, and
the activation promoting effects of CD4-MHCII interactions
(summarized in Table 3). Thus, IL-2 inhibition is affected by
CD4-Lck sequestration, CD4-pMHCII interaction, and by a
CD4-dependent mechanism in an afﬁnity- and formatdependent manner.

gen and LLO118 TCR SCS 4-1BB clones were dropped due to
their poor performance in the ﬁrst IL-2 tests. The 58-/- CD4- T
cell hybridoma cell line (CD4-) lack CD4, which allows Lck to
interact freely with the TCR-pMHCII complex and nulliﬁes
CD4-MHCII interactions (Figure 6A). The 58-/- CD4+ T cell
hybridoma cell line (CD4+) has wild type CD4 which sequesters
Lck to its cytoplasmic tail and binds to MHCII (Figure 6B). 58-/CD4T+ T cell hybridoma line (CD4T+) is truncated C-terminally
(maintains amino acids 1-421) which allow Lck to colocalize but
not bind to CD4 while CD4 still binds to MHCII (Figure 6C)
(60, 70). CD4T expressed in both T cells and hybridomas has
been documented in many sources to not bind Lck (60, 70, 71)
and is suggested to produce IL-2 in a Lck-independent manner
(60, 70, 71). Previous work has also demonstrated in cells that,
while CD4TDbind does not bind MHCII, it still contains the
cytoplasmic tail necessary for binding Lck (72, 73).Finally, 58-/CD4T+ Dbind (CD4T+ Dbind) frees Lck and is mutated to
prevent CD4 binding to MHCII by altering residues 68–73
from KGVLIR to DGDSDS (Figure 6D) (60).
CD4T+ and CD4T + Dbind constructs were retrovirally
transduced into existing CD4- T cell hybridomas containing
TCR-SCS or ﬂTCR constructs and the clones were sorted for
GFP, TCR, and CD4 expression by ﬂow sorting. CD4- hybridomas
did not express CD4, and there was consistent CD4 expression
between the various CD4+ clones (Supplemental Figure S8) while
GFP levels varied (Supplemental Figure S9A). TCR surface
expression was consistent across cell lines for most TCR
constructs, except LLO56low and LLO56int CD28 clones which
were most stably expressed in CD4+ cells (p < 0.0001 and p <
0.0001, respectively) (Supplemental Figure S9B). Similarly,
avidity measured by tetramer was mainly consistent between
clones except for LLO56low 4-1BB where CD4- had higher
avidity than all CD4+ clones (p = 0.0014), and LLO118int CD28
where CD4+ clone had the highest avidity (p = 0.0063)
(Supplemental Figure S9C).
As expected, LLO56low ﬂTCR IL-2 production was promoted
by the presence of CD4-MHCII interactions (CD4+ p = 0.0105
and CD4T+ p = 0.0014) and the absence of CD4-MHCII
interaction in the CD4- and CD4T+ Dbind abrogated LLO56low
ﬂTCR IL-2 production (Figure 6E). CD4 Lck-sequestration did
not affect LLO56low ﬂTCR IL-2 production since the CD4+ and
CD4T+ clones responded the similarly to antigen (Figure 6E). In
contrast, intermediate afﬁnity LLO56int ﬂTCR IL-2 production is

TABLE 3 | Summary of Figures 6.
low

LLO56

LLO118

ﬂTCR
4-1BB
CD28
CD28
3rd gen

int

high

CD4

Lck-free

CD4-MHCII

CD4

Lck-free

CD4-MHCII

CD4

Lck-free

CD4-MHCII

NA
–
+

NA
+
NA

+
NA
NA

NA
NA
NA
NA

+
+
+
+
+

NA
+
+
+
+

NA

+
+

NA
NA

IL-2 production data interpretation broken down into base TCR (LLO56 or LLO118), construct, and TCR-pMHCII afﬁnity. “-” indicates that the condition inhibits or does not promote IL-2
production, “NA” indicates that effects on IL-2 production were “not appreciable”, and “+” indicates that the condition promotes or least does not inhibit IL-2 production. Bolded interior
boxes highlight the phenotype shared by intermediate afﬁnity ﬂTCR and high afﬁnity TCR-SCS clones.
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determines MHC restriction (78), and coreceptor-Lck binding
stoichiometry is the limiting factor for signaling during selection
(80). In particular, CD8, which binds Lck more preferentially
than CD4, has a greater effect on TCR selection and increases
CD8+ T cell reactivity to low afﬁnity and self-reactive antigen
compared to CD4+ T cells (80). In both mature CD8+ T cells and
T cell hybridomas, free Lck has higher mobility, more activating
Y394 phosphorylation, higher kinase activity, and mediated
higher T cell activation compared to coreceptor-bound Lck
(81). Additionally, during activation, TCR-CD3 is ﬁrst
phosphorylated by unbound-Lck followed by MHC-dependent
CD3-CD8 interaction and the less activated coreceptor-bound
Lck (82–84). CD4-bound Lck activation may be reliant on a
mechanism distinct from CD4-free Lck activation, which is
likely mediated by tyrosine-protein kinase Fyn and may
obscure mechanism comparison (37, 85, 86). Additionally, it
is also possible that CD4 may function differently in T cells
expressing native TCRs or CAR cytoplasmic domains. However,
despite these potential complications, CD4-Lck-dependent
inhibition could occur in two fashions. First, optimal TCR
afﬁnity-mediated signaling is dependent on ﬁne-tuning the
intensity and duration of the Lck phosphorylation cascade and
high afﬁnity TCRs may have early intense Lck phosphorylation
resulting in acute transient activation (87). Conversely, if
CD4 is not recruited to the TCR, it could sequester Lck away
from the activation complex, which prevents the activation
phosphorylation cascade thereby attenuating T cell activation
(49). The ﬁrst option suggests that all high-afﬁnity TCR signaling
would be attenuated regardless of whether Lck was interacting
with CD4; however, IL-2 output reduction in the presence of
CD4-Lck sequestration is clearly demonstrated by our
intermediate and high afﬁnity CD4+ T cell hybridoma clones.
It is also possible that with an increase in afﬁnity and the
subsequent decrease in off-rate or increase in half-life, CD4Lck fails to cycle through the TCR-pMHC synapse, thereby
decreasing CD3 phosphorylation and thus downstream
activation. Signaling activation is affected by both TCRpMHCII dwell time and CD4-Lck interactions (70, 88, 89).
CD4 increases TCR signaling on low-afﬁnity pMHCII by
increasing TCR-CD3 dwell time (39). CD4 dwell time on
pMHCII is proportional, yet faster, to TCR dwell time,
suggesting that TCR:pMHCII interaction kinetics would
directly affect the duration that CD4 molecules cycle through
the immunological synapse in a processive-like manner (88).
Additionally, compared to coreceptor-bound Lck, CD4-free Lck
is phosphorylated more at its Y394 activation site, with higher
kinase activity and mobility (81); thus, it may be that if CD4-free
Lck is prevented from interacting with the immunological
synapse, activation may be reduced. TCR-pMHCII interactions
are highly ordered and uniform, increasing the likelihood
that the spatial relationship between Lck and the ITAMs of
the TCR-SCS or ﬂTCRs are consistent. Thus, kinetic factors,
such as TCR-pMHCII afﬁnity would greatly inﬂuence the
stability of the macrocomplex and consequently the duration
of Lck interactions with the ITAMs (39, 90). These kinetics
alone could explain the drop in activation observed for our

DISCUSSION
Here, we engineered and characterized a panel of MHCIIspeciﬁc TCRs with increasing pMHC afﬁnity in order to
interrogate the relationships between TCR format, TCRpMHCII afﬁnity, and the coreceptor CD4 on CD4+ T cell
activation. In addition to the generation of a high afﬁnity
MHCII-dependent TCR model, we identify a CD4-dependent
phenotype potentially relevant for cancer-immunotherapeutic
development and show that high afﬁnity ﬂTCRs outperform
TCR-SCS formats, that TCR-SCS format effects on T cell
activation are more dependent on the TCR than the TCR-SCS
format, and that CD4 can inhibit both ﬂTCR and TCR-SCS
activation in an Lck dependent and independent fashion. This
study utilized 58-/- T cell hybridomas as a proxy for T cell
activation activity. While not as physiologically relevant as using
primary T cells, this system has the advantage of enabling the
survey of T cell activation characteristics for multiple constructs
as we have done here and has been frequently used as a
springboard for further exploration of high afﬁnity TCRs in
primary T cells (47, 65, 74, 75). The contributions of these factors
were assessed using IL-2 production, which is a proxy, but not a
complete indication of T cell activation. ﬂTCRs produced more
IL-2 than all TCR-SCS constructs at each afﬁnity level and IL-2
production generally increased with rising TCR afﬁnity for all
constructs. In low afﬁnity TCRs, CD4 enhanced IL-2 production
for both ﬂTCR and TCR-SCS formats. For intermediate or high
afﬁnity TCR clones, IL-2 production was abrogated by CD4-Lck
sequestration and an unknown CD4-dependent mechanism.
These effects, activation promotion by increased afﬁnity and
CD4-MHCII, or activation suppression by Lck-sequestration
and CD4 itself, had unique afﬁnity thresholds that are
dependent on construct type (ﬂTCR or TCR-SCS). Lck
sequestration affected activation for all intermediate and high
afﬁnity constructs, while CD4-MHCII ceased to promote
activation and CD4-dependent inhibition repressed IL-2
production at unique afﬁnity thresholds for ﬂTCR constructs
(intermediate afﬁnity) and TCR-SCS constructs (high afﬁnity). It
is possible that Lck sequestration or the constructs themselves,
have unique and important effects on other activation markers
(such as the early activation markers CD25, pLCk, pCD3z,
pERK, CD69), inhibitory markers (such as PD1 and LAG3),
tonic signaling, T cell proliferation and effector function, which
should be investigated in primary T cells in the future.
The balance of free unbound Lck and coreceptor-bound Lck
affects T cell developmental fate, and T cell responsiveness in the
periphery. Following colocalization to the TCR, CD4 signals via
Lck bound to its cytoplasmic tail (68, 69). Lck phosphorylates
immune-receptor tyrosine-based activating motifs (ITAMs) of
the CD3 subunits of the TCR complex, which then initiates other
early signaling machinery of the T cell (69, 76, 77). Bound and
unbound Lck signal independently and can alter T cell
development and function (78, 79). During thymic selection,
the intracellular coreceptor-bound or unbound state of Lck
determines whether ab TCRs are MHC-restricted or
independent (78). Lck association with coreceptor proteins
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production (99). For example, CD28-CAR constructs, which can
directly bind Lck, are well known for their Lck-binding-dependent
enhanced IL-2 production, increased tonic signaling, and
subsequent T cell exhaustion compared to 4-1BB CARs (100–
103). Thus, the observed increase in IL-2 production for TCRSCS CD28 constructs may be attributable to the innate
characteristics of CD28-intracellular signaling domains rather
than increased stable surface expression. As CD28-CARs
phosphorylate CD3 more quickly yet do not exceed the levels of
CD3 phosphorylation exhibited by 4-1BB CARs, this may be due to
signaling intensity (101). Additionally, because CD28 recruits Lck
to lipid rafts where it associates with CD4, CD28 may be better able
to recruit Lck (104, 105). While TCR-SCS 3rd generation constructs
had mixed activation success and overall reduced cytokine
production compared to TCR-SCS CD28 constructs, this may be
attributable to 3rd generation CAR T cells improved expansion and
persistence and may mimic some characteristics of 4-1BB CAR T
cells, like reduced cytokine production (106, 107). Our TCR-SCS
CD28 constructs demonstrated similarities to antibody-based
CD28 CARs, including enhanced tonic signaling in some clones,
suggesting that TCR SCS CD28 may also have increased T cell
exhaustion. However, unlike CD28 CARs, CD4 expression
ameliorated tonic signaling in our TCR-SCS constructs. It will be
important to examine the role of CD4 in primary T cells to
determine if CD4 prevents exhaustion in clones expressing TCRSCS CD28 constructs.
CD4+ T cells are promising newcomers to immunotherapy.
CD4+ TCRs convey exquisite target speciﬁcity and direct robust
immune responses through indirect mechanisms that avoid
tumor antigen escape. While much development and thought
has been devoted to the activation beneﬁts and off-target effects
of increased TCR-pMHC afﬁnity, especially for CD8+ TCRs,
further TCR-therapeutic development should give consideration
to the unique afﬁnity thresholds of TCR-SCS and ﬂTCR formats
and the potential inhibitory effects of CD4.

high-afﬁnity, slow off-rate TCR clones. To support this idea, CD8
also acts as a dominant negative inhibitor for ligands that do not
recruit fresh CD8 to the TCR-CD3 complex (49).
Previous research suggests that CD4 can send an inhibitory
signal independent of Lck via post activation antibody-mediated
ligation, which attenuates IL-2 production and ongoing activated
T cell response (91). This response was also observed in a clonal
variant expressing a form of CD4 unable to associate with Lck,
suggesting that CD4 has independent inhibitory or regulatory
function (91). Furthermore, CD4-mediated inhibition has also
been observed during CD4-MHCII interactions leading to a
decrease in IL-2 mRNA (91). While we did not seek the source
for our Lck-independent CD4 inhibition nor acquire IL-2 mRNA
levels, we noted that there was an afﬁnity threshold for this
behavior that was independent of MHC interaction, and
therefore may be a unique mechanism to that reported in
Chervin et al. (49). The afﬁnity threshold for this Lckindependent CD4 inhibition was lower for ﬂTCR (intermediate
afﬁnity) than TCR-SCS (high afﬁnity). This may be due to
the signaling power of each construct: ﬂTCR-CD3 complexes
have 10 ITAMs with 20 tyrosine residues available for
phosphorylation, whereas TCR-SCS domains have only 3
ITAMs and 6 tyrosine residues (47, 92, 93). The increased
availability of ITAMs per activated Lck may also explain why
LLO56int ﬂTCR experienced less IL-2 production inhibition in
the presence of CD4—more signal per Lck molecule despite
CD4-Lck movement restriction. Whether SCS-TCRs function as
dimers is unclear and remains a topic of study (67, 94, 95). It is
also curious that the CD4-MHCII interaction supports activation
in intermediate afﬁnity TCR-SCS clones, suggesting that while
CD4 may not contribute to the overall afﬁnity of TCR-SCS
constructs, it may stabilize the interaction between TCRpMHCII or provide an additional Lck-independent activation
signal. The increased interaction stability is more likely as high
afﬁnity TCR-SCS IL-2 production is not signiﬁcantly improved
when CD4 interacts with MHCII, suggesting high afﬁnity
constructs likely have stable interactions independent of CD4
contributions. Taken together this data suggests an afﬁnity
threshold where, up to a point, increased time for CD4-MHCII
interactions improves TCR-dependent signaling when it is not
Lck-limited, but after a certain afﬁnity point, increased dwell
time slows TCR-dependent signaling and positive beneﬁts of
CD4-MHCII interactions become redundant.
In addition to the stability challenges presented by scTCR
format, the TCR-SCS intracellular format also affected the
stability of each TCR. TCR-SCS CD28 format was more stably
expressed than other TCR-SCS or ﬂTCR formats, and as noted in
other studies, the enhanced surface expression of TCR-SCS CD28
formats via increased stability may explain their improved avidity
and T cell activation (96–98). However, it is difﬁcult to ascertain
whether the increased IL-2 production of TCR-SCS CD28 is due to
enhanced stable surface expression or the innate characteristics of
CD28-intracellular signaling domains. As observed in numerous
antibody-based CAR studies comparing CD28 domains to 4-1BB
domains, intracellular signaling domains differentially impact
multifactorial T cell response characteristics, including cytokine
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CDR3b mutations for additional clones are listed below the sequence map.

FUNDING

SUPPLEMENTARY FIGURE 6 | GFP expression levels for CD4- and CD4+
clones. GFP MFI is signiﬁcantly different for most scTCR and ﬂTCR constructs
between CD4- and CD4+ pairs including LLO56low 4-1BB (p < 0.0001), LLO56int 41BB (p < 0.0001), LLO56low CD28 (p = 0.0016), LLO56int CD28 (p = 0.0001),
LLO56low 3rd gen (p = 0.0054), LLO56int 3rd gen (p < 0.0001), LLO56low ﬂTCR (p =
0.0058), LLO118low 4-1BB (p < 0.0001), LLO118int 4-1BB (p < 0.0001), LLO118low
CD28 (p < 0.0001), LLO118int CD28 (p = 0.0012), LLO118int 3rd gen (p < 0.0001),
and LLO118high 3rd gen (p < 0.0001).

This work was supported by a R15 grant to KW (R0102063) from
the National Institutes of Health, Simmons Center for Cancer
Research Summer Fellowships and Graduate Student Fellowship
grants at Brigham Young University to DJ.

ACKNOWLEDGMENTS
SUPPLEMENTARY FIGURE 7 | Comparison of IL-2 production at 10-3 M
peptide stimulation. Analysis of levels of IL-2 production from Figure 5 at 10-3 M
peptide stimulation. IL-2 production between 58-/-CD4- afﬁnity clones was
signiﬁcantly different for LLO56low and LLO56int 4-1BB (p = 0.0211), LLO56low
and LLO56int CD28 (p = 0.0039) and LLO56low and LLO56int ﬂTCR (p = 0.0033),
LLO118low and LLO118int 3rd gen (p = 0.0006), LLO118low and LLO118high 3rd
gen (p = 0.0070), LLO118low and LLO118int 4-1BB (p = 0.0441), LLO118low and
LLO118high 4-1BB (p = 0.0115), LLO118low and LLO118int CD28 (p = 0.0489),
LLO118low and LLO118high CD28 (p < 0.0001), and LLO118int and LLO118high
CD28 (p < 0.0001).

We thank National Institutes of Health Tetramer Core Facility at
Emory University for providing the MHC tetramers. We thank
Dr. Claudia Tellez Freitas for her help with initial cell culture
training and advice. We thank Dr. Dan Harris and Dr. David
Kranz (University of Illinois Urbana-Champaign) for Platinum
Ecotrophic, 58-/- and 58-/- CD4+ cell hybridoma lines, TCR-SCS
constructs and ﬂTCR expression advice. We also thank Dr.
Michael Kunz (University of Arizona) for CD4T+ and CD4T+
D bind constructs and for his excellent critical review of
the manuscript.

SUPPLEMENTARY FIGURE 8 | CD4 is not expressed in CD4- SCS-TCR, ﬂTCR
and base 58-/- hybridoma cell lines. Twenty-ﬁve thousand cells were stained with
antibody mix for 10 mins. 10,000 events collected via ﬂow cytometry. (A) Isotype
stain LLO56high CD28, LLO56high ﬂTCR, and base 58-/- T cell hybridoma lines not
expressing TCRs were stained with antibody mix [anti-Vb2 PE, anti-Va APC, and
anti-F4/80 PE Cy7 (rat IgG2, Fisher Scientiﬁc)]. Histograms display anti-F4/80 PECy7: Cells only (grey), CD4- clones (green), and all CD4+ clones (red) including
CD4+, CD4T+ and CD4T+ Dbind. (B) CD4 stain of LLO56high CD28, LLO56high
ﬂTCR, and base 58-/- T cell hybridoma lines not expressing TCRs were stained with
antibody mix [anti-Vb2 PE, anti-Va APC, and anti-CD4 PE Cy7 (rat IgG2, Fisher
Scientiﬁc)]. Histograms display anti-F4/80 PE-Cy7: Cells only (grey), CD4- clones
(blue), and all CD4+ clones (red) including CD4+, CD4T+ and CD4T+ Dbind.
(C) Comparison of isotype stain (green) and CD4 stain (blue) for CD4-.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at:
https://www.frontiersin.org/articles/10.3389/ﬁmmu.2020.561889/
full#supplementary-material
SUPPLEMENTARY FIGURE 1 | LLO118 and LLO56 single-chain TCRs
stabilizing mutations. Wild type templates (LLO118WT and LLO56WT) compared to
stabilized single-chain TCR (scTCR) templates (LLO118low and LLO56low). The
original LLO56WT scTCR template included mutations of the amino acid K42bG,
H36aY and S74aT (highlighted gray) known to enhance surface display levels in
related TCRs (108). Stability mutations selected by random mutagenesis and
directed evolution are marked in red. Boxed amino acids show joint LLO118low and
LLO56low selection (K42bG and T93bA), and mutations in another known stability
hotspot (L45aI and I49aM) are unmarked. LLO118low independently selected
I115aK, and LLO56low selected T93bA and S9aT.

SUPPLEMENTARY FIGURE 9 | GFP expression levels for SCS constructs (A)
GFP expression by construct in order of 58-/- CD4-, 58-/- CD4+, 58-/- CD4T+, 58-/CD4T+ Dbind T cell hybridomas. Both CD4T+ and CD4T+ Dbind and TCRs were
inserted into the cell lines via the vector pMIGII which uses GFP as a reporter gene. Thus,
the GFP expression for all CD4T+ and CD4T+ Dbind cell lines are signiﬁcantly higher than
CD4- and CD4+ cell lines. LLO56low (pink colors), LLO56int (red colors), LLO118int (light
blue colors), LLO118high (dark blue colors). Hatched lines indicate CD4-MHC
interactions. LLO56low 4-1BB (p < 0.0001), LLO56int 4-1BB (p < 0.0001), LLO56low
CD28 (p < 0.0001), LLO56int CD28 (p < 0.0001), LLO118int 3rd gen (p < 0.0001),
LLO118high 3rd gen (p < 0.0001), LLO118int CD28 (p < 0.0001), and LLO118high CD28
(p < 0.0001). (B) Stable expression of Vb2 by construct. LLO56low CD28 (p < 0.0001)
and LLO56int CD28 (p < 0.0001) (C) To ascertain whether avidity was maintained within
each TCR-construct despite CD4 variations, each cell line was tested at sub-saturating
tetramer concentrations: LLO56low (10-8 M), LLO56int (5 x 10-10 M), LL0118int (10-9 M),
and LL0118high (5 x 10-10 M). Colors and order as found in (B). LLO118int CD28 (p =
0.033). Groups analyzed for differences with one-way ANOVA.

SUPPLEMENTARY FIGURE 2 | Protein sequence map for 4-1BB SCS-TCR
formats for (A) LLO56low and LLO56int, and (B) LLO118low, LLO118int, and
LLO118high. Protein fragments are delineated by color bar above the amino acid
sequence. Stability mutations (highlighted grey or red font) are marked as indicated
in Supplemental Figure 1. CDR3b mutations for additional clones are listed below
the sequence map.
SUPPLEMENTARY FIGURE 3 | Protein sequence map for CD28 SCS-TCR
formats for (A) LLO56low and LLO56int, and (B) LLO118low, LLO118int, and
LLO118high. Protein fragments are delineated by color bar above the amino acid
sequence. Stability mutations (highlighted grey or red font) are marked as indicated
in Supplemental Figure 1. CDR3b mutations for additional clones are listed below
the sequence map.

SUPPLEMENTARY TABLE 1 | Summary of T cell responses of LLO56 and
LLO118 to antigen adapted from Persaud et al. LLO118 and LLO56 differentially
respond to activation by peptide LLO190-205. LLO118 and LLO56 have similar
proliferation responses to LLO190-205 in vitro, but in vivo LLO118 has a more robust
primary response while LLO56 has a more robust secondary response. LLO56
produces more IL-2 in vitro and undergoes higher rates of apoptosis during the primary
response than LLO118. Surface plasma resonance measurements of LLO56 and
LLO118 dissociation constants are 27.4 and 28.3 µM, respectively (41, 42).

SUPPLEMENTARY FIGURE 4 | Protein sequence map for 3rd gen SCS-TCR
formats for (A) LLO56low and LLO56int, and (B) LLO118low, LLO118int, and
LLO118high. Protein fragments are delineated by color bar above the amino acid
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